Ishikawa / Kim / König Pharmacogenomics of Human Drug Transporters

Clinical Impacts
1. Auflage 2013
ISBN: 978-1-118-35320-2
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 440 Seiten, E-Book

Sets the foundation for safer, more effective drugtherapies

With this book as their guide, readers will discover how toapply our current understanding of the pharmacogenomics of drugtransporters to advance their own drug discovery and developmentefforts. In particular, the book explains how new findings in thefield now enable researchers to more accurately predict druginteractions and adverse drug reactions. Moreover, it sets thefoundation for the development of drug therapies that are tailoredto an individual patient's genetics.

Pharmacogenomics of Human Drug Transporters serves as acomprehensive guide to how transporters regulate the absorption,distribution, and elimination of drugs in the body as well as howan individual's genome affects those processes. The book's eighteenchapters have been authored by a team of leading pioneers in thefield. Based on their own laboratory and clinical experience aswell as a thorough review of the literature, these authors exploreall facets of drug transporter pharmacogenomics, including:

* Individual drug transporters and transporter families and theirclinical significance

* Principles of altered drug transport in drug-druginteractions, pharmacotherapy, and personalized medicine

* Emerging new technologies for rapid detection of geneticpolymorphisms

* Clinical aspects of genetic polymorphisms in major drugtransporter genes

* Future research directions of drug transporter pharmacogenomicsand the prospect of individualized medicine

Pharmacogenomics of Human Drug Transporters opens thedoor to new drug discovery and development breakthroughs leading tosafer and more effective customized drug therapies.The book isrecommended for pharmaceutical scientists, biochemists,pharmacologists, clinicians, and genetics and genomicsresearchers.

Autoren/Hrsg.

Ishikawa, Toshihisa

Kim, Richard B.

König, Jörg

Inhaltsverzeichnis

PREFACE vii
CONTRIBUTORS ix
CHAPTER 1 INTRODUCTION TO PHARMACOGENOMICS OF DRUG TRANSPORTERS1
Marianne K. DeGorter and Richard B. Kim
CHAPTER 2 ADME PHARMACOGENOMICS IN DRUG DEVELOPMENT 13
Liangfu Chen and Joseph W. Polli
CHAPTER 3 REGULATORY PERSPECTIVE ON PHARMACOGENOMICS OFDRUG-METABOLIZING ENZYMES AND TRANSPORTERS 39
Lei Zhang, Gilbert J. Burckart, Lawrence J. Lesko and Shiew-MeiHuang
CHAPTER 4 THE PHARMACOGENOMICS OF MEMBRANE TRANSPORTERS PROJECT73
Sook Wah Yee, Deanna L. Kroetz and Kathleen M. Giacomini
CHAPTER 5 EMERGING NEW TECHNOLOGY OF SNP TYPING 109
Toshihisa Ishikawa and Yoshihide Hayashizaki
CHAPTER 6 OATP1A2, OAT1, AND OAT3 125
Rommel G. Tirona
CHAPTER 7 OATP1B1, OATP1B3, AND OATP2B1 141
J¨org K¨onig and Martin F. Fromm
CHAPTER 8 OCT (SLC22A) AND OCTN FAMILY 171
Sophie L. Stocker, Arian Emami Riedmaier, Matthias Schwab andKathleen M. Giacomini
CHAPTER 9 MATE (SLC47) FAMILY 209
Atsushi Yonezawa and Ken-ichi Inui
CHAPTER 10 PEPT (SLC15A) FAMILY 223
Tomoko Sugiura, Saki Umeda, Akira Tsuji and Yukio Kato
CHAPTER 11 NUCLEOSIDE TRANSPORTERS (SLC28 AND SLC29) FAMILY243
M´yriam Molina-Arcas and Marc¸alPastor-Anglada
CHAPTER 12 P-GLYCOPROTEIN (MDR1/ABCB1) 271
Ingolf Cascorbi
CHAPTER 13 BSEP (ABCB11) 295
Bruno Stieger and Gerd A. Kullak-Ublick
CHAPTER 14 BCRP (ABCG2) 311
Agnes Basseville, Susan E. Bates, William D. Figg and AlexSparreboom
CHAPTER 15 MRP2 (ABCC2) AND MRP3 (ABCC3) 345
Anne T. Nies
CHAPTER 16 MRP4 (ABCC4) 365
Satish B. Cheepala, Mugdha Sukthankar and John D.Schuetz
CHAPTER 17 MRP8 (ABCC11) 387
Yu Toyoda and Toshihisa Ishikawa
CHAPTER 18 FUTURE PERSPECTIVES 401
Toshihisa Ishikawa and Joseph Ware
INDEX 417

Über Autor(innen)

TOSHIHISA ISHIKAWA, PhD, is Senior Scientist at RIKENYokohama Institute and Professor of Biochemistry, MolecularBiology, and Pharmacogenomics at Yokohama City University'sGraduate School of Medicine. Previously, Dr. Ishikawa was theDirector of the Department of Research Technology Development atPfizer, Japan. A recipient of the Achievement Award from theInternational Life Sciences Institute (ILSI), Dr. Ishikawa is alsothe cofounder of the International Transporter Consortium(ITC).
RICHARD B. KIM, MD, FRCPC, is Professor and Chair of theDivision of Clinical Pharmacology and Associate Chair for Researchin the Department of Medicine at the University of Western Ontario.He is a Fellow of the American Association of PharmaceuticalScientists and an elected member of the American Society forClinical Investigation.
JÖRG KÖNIG, PhD, is Professor and Headof the Molecular Biology Laboratories in the Department of ClinicalPharmacology at the Friedrich-Alexander UniversitätErlangen-Nürnberg.